Clinical research on RSV prevention in children and pregnant women: progress and perspectives

Respiratory syncytial virus (RSV) is a significant causative agent of bronchitis and pneumonia in infants and children. The identification and structural analysis of the surface fusion glycoprotein of RSV represents a pivotal advancement in the development of RSV prevention. This review provides a c...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1329426
Main Authors Gong, Xuejia, Luo, Erdan, Fan, Li, Zhang, Wanggang, Yang, Yan, Du, Yuhua, Yang, Xiao, Xing, Shasha
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.01.2024
Subjects
Antibodies, Viral
Child
children
clinical trial
Female
Humans
Immunology
Infant
Infant, Newborn
monoclonal antibody
Pregnancy
Pregnant Women
Respiratory Syncytial Virus Infections
Respiratory Syncytial Virus Vaccines
Respiratory Syncytial Virus, Human
RSV vaccines
Vaccination
clinical trial
pregnant women
RSV vaccines
monoclonal antibody
children
Online AccessGet full text

Cover

More Information
Summary:Respiratory syncytial virus (RSV) is a significant causative agent of bronchitis and pneumonia in infants and children. The identification and structural analysis of the surface fusion glycoprotein of RSV represents a pivotal advancement in the development of RSV prevention. This review provides a comprehensive summary of RSV monoclonal antibody (mAb) and vaccine clinical trials registered on ClinicalTrials.gov, emphasizing on the classification, name, target, phase, clinical outcomes, and safety data of RSV vaccination in newborns, infants and children. We also discuss the characteristics of the types of RSV vaccines for maternal immunity and summarize the current clinical research progress of RSV vaccination in pregnant women and their protective efficacy in infants. This review will provide new ideas for the development of RSV prevention for children in the future.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Salman Sadullah Usmani, Albert Einstein College of Medicine, United States
Larry Ellingsworth, Novavax, Inc., United States
These authors have contributed equally to this work
Reviewed by: Roopali Rajput, Jamia Hamdard University, India
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1329426